Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: A systematic review and meta-analysis

European Journal of Clinical Pharmacology

Volumn 66, Issue 11, 2010, Pages 1071-1079

  Alavian, Seyed Moayed ^a   Behnava, Bita ^a   Tabatabaei, Seyed Vahid ^a  

^a Baqiyatallah Medical Sciences University Baqyatallah Hospital   (Iran)

Author keywords

Consensus interferon; High dose; Induction therapy; Low dose; Meta analysis; Systematic review

Indexed keywords

CONSENSUS INTERFERON;

ANEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649319383     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0881-7     Document Type: Review

References (57)

1. MH Ahmadipour SM Alavian S Amini K Azadmanesh 2005 Hepatitis C virus genotypes Hepat Mon 5 3 77 82
2. M Arens 2001 Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV J Clin Virol 22 1 11 29 1:CAS:528:DC%2BD3MXksVGqtbk%3D 10.1016/S1386-6532(01)00156-1 11418349 (Pubitemid 32551946)
3. D Lavanchy 2009 The global burden of hepatitis C Liver Int 29 Suppl 1 74 81 10.1111/j.1478-3231.2008.01934.x 19207969
4. LB Seeff 2002 Natural history of chronic hepatitis C Hepatology 36 5 Suppl 1 S35 S46 10.1002/hep.1840360706 12407575
5. J Berenguer J Alvarez-Pellicer PM Martin J Lopez-Aldeguer MA Von-Wichmann C Quereda, et al. 2009 Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2 407 413 1:CAS:528:DC%2BD1MXhtVKrtrzL 10.1002/hep.23020 19575364
6. AK Singal A Singh S Jaganmohan P Guturu R Mummadi YF Kuo, et al. 2010 Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis Clin Gastroenterol Hepatol 8 2 192 199 10.1016/j.cgh.2009.10.026 19879972
7. S Breitenstein D Dimitroulis H Petrowsky MA Puhan B Mullhaupt PA Clavien 2009 Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis Br J Surg 96 9 975 981 1:CAS:528:DC%2BD1MXhtFGmtLvJ 10.1002/bjs.6731 19672926
8. T Poynard J McHutchison M Manns C Trepo K Lindsay Z Goodman, et al. 2002 Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 5 1303 1313 1:CAS:528:DC%2BD38Xkt1Cru74%3D 10.1053/gast.2002.33023 11984517
9. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17(4):287-292
10. T Poynard V Leroy P Mathurin M Cohard P Opolon JP Zarski 1996 Treatment of chronic hepatitis C by interferon for longer duration than six months Dig Dis Sci 41 12 Suppl 99S 102S 1:STN:280:DyaK2s7kvVOqtA%3D%3D 10.1007/BF02087883 9011484
11. JH Hoofnagle AM di Bisceglie 1997 The treatment of chronic viral hepatitis N Engl J Med 336 5 347 356 1:STN:280:DyaK2s7ls1ahuw%3D%3D 10.1056/NEJM199701303360507 9011789 (Pubitemid 27057187)
12. T Poynard V Leroy M Cohard T Thevenot P Mathurin P Opolon, et al. 1996 Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Hepatology 24 4 778 789 1:CAS:528:DyaK28XmvFOisb4%3D 10.1002/hep.510240405 8855176
13. R Lin E Roach M Zimmerman S Strasser GC Farrell 1995 Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group J Hepatol 23 5 487 496 1:CAS:528:DyaK28Xjt1ym 10.1016/0168-8278(95)80052-2 8583134
14. RL Carithers Jr SS Emerson 1997 Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials Hepatology 26 3 Suppl 1 83S 88S 1:CAS:528: DyaK2sXmt1Ckt7g%3D 10.1002/hep.510260715 9305670
15. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 21 1485 1492 1:CAS:528:DyaK1cXnslGmtbs%3D 10.1056/NEJM199811193392101 9819446 (Pubitemid 28543496)
16. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo, et al. 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 9138 1426 1432 1:CAS:528:DyaK1cXnsVSmsLg%3D 10.1016/S0140-6736(98)07124-4 9807989 (Pubitemid 28510876)
17. MY Lai JH Kao PM Yang JT Wang PJ Chen KW Chan, et al. 1996 Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C Gastroenterology 111 5 1307 1312 1:CAS:528:DyaK28XmvFygsbk%3D 10.1053/gast.1996.v111.pm8898645 8898645 (Pubitemid 26362256)
18. P Ferenci E Formann H Laferl M Gschwantler F Hackl H Brunner, et al. 2006 Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection J Hepatol 44 2 275 282 1:CAS:528:DC%2BD28Xktl2qsw%3D%3D 10.1016/j.jhep.2005.09.015 16338019 (Pubitemid 43069208)
19. F Bosques-Padilla R Trejo-Estrada O Campollo-Rivas C Cortez-Hernandez M Dehesa-Violante H Maldonado-Garza, et al. 2003 Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial Ann Hepatol 2 3 135 139 15115965
20. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin, et al. 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 5 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
21. IM Jacobson RS Brown Jr B Freilich N Afdhal PY Kwo J Santoro, et al. 2007 Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 4 971 981 1:CAS:528:DC%2BD2sXht1aksrzE 10.1002/hep.21932 17894303 (Pubitemid 350144761)
22. SA Gonzalez EB Keeffe 2009 Management of chronic hepatitis C treatment failures: role of consensus interferon Biologics 3 141 150 1:CAS:528: DC%2BD1MXmsFSmtLw%3D 19707403
23. A Liberati DG Altman J Tetzlaff C Mulrow PC Gotzsche JP Ioannidis, et al. 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 4 W65 W94 19622512
24. LL Gluud 2006 Bias in clinical intervention research Am J Epidemiol 163 6 493 501 10.1093/aje/kwj069 16443796
25. L Bax LM Yu N Ikeda H Tsuruta KG Moons 2006 Development and validation of MIX: comprehensive free software for meta-analysis of causal research data BMC Med Res Methodol 6 50 10.1186/1471-2288-6-50 17038197 (Pubitemid 44662384)
26. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis, 1st edn. Wiley, London
27. Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New York
28. JP Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 7414 557 560 10.1136/bmj.327.7414.557 12958120
29. G Alaimo V Di Marco D Ferraro R Di Stefano S Porrovecchio F D'Angelo, et al. 2006 Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial World J Gastroenterol 12 42 6861 6864 1:CAS:528:DC%2BD28XhtlCkur7O 17106937
30. WO Bocher M Schuchmann R Link H Hillenbrand F Rahman M Sprinzl, et al. 2006 Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy Liver Int 26 3 319 325 10.1111/j.1478-3231.2005.01239.x 16584394 (Pubitemid 43349322)
31. M Cornberg J Hadem E Herrmann F Schuppert HH Schmidt M Reiser, et al. 2006 Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study J Hepatol 44 2 291 301 1:CAS:528:DC%2BD28Xktl2qsQ%3D%3D 10.1016/j.jhep.2005.10.021 16360972 (Pubitemid 43069210)
32. G Fattovich I Zagni E Minola M Felder P Rovere A Carlotto, et al. 2003 A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C J Hepatol 39 5 843 849 1:CAS:528:DC%2BD3sXotVert7g%3D 10.1016/S0168-8278(03)00391-X 14568269 (Pubitemid 37372196)
33. PJ Gaglio M Rodriguez-Torres R Herring B Anand T Box M Rabinovitz, et al. 2004 Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy J Clin Gastroenterol 38 7 599 604 1:CAS:528:DC%2BD2cXltlOrsrk%3D 10.1097/00004836-200408000-00012 15232365 (Pubitemid 38955419)
34. EJ Heathcote S James KD Mullen SC Hauser H Rosenblate DG Albert Jr 1999 Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group Hepatology 30 2 562 566 1:CAS:528:DyaK1MXlt1ajsLs%3D 10.1002/hep.510300202 10421669 (Pubitemid 29357526)
35. N Hirashima E Orito K Ohba H Kondo T Sakamoto S Matsunaga, et al. 2004 A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load Hepatol Res 29 1 9 12 1:CAS:528:DC%2BD2cXjvVansro%3D 10.1016/j.hepres.2004.01.002 15135340 (Pubitemid 38594505)
36. SJ Hwang SD Lee CY Chan RH Lu FY Chang 1999 A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C Am J Gastroenterol 94 9 2496 2500 1:CAS:528: DyaK1MXmt1Kqtbo%3D 10.1111/j.1572-0241.1999.01382.x 10484014 (Pubitemid 29420679)
37. DM Jensen EL Krawitt EB Keeffe FB Hollinger SP James K Mullen, et al. 1999 Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group Am J Gastroenterol 94 12 3583 3588 1:CAS:528: DC%2BD3cXlslaitQ%3D%3D 10.1111/j.1572-0241.1999.01651.x 10606323
38. JH Kao PJ Chen MY Lai DS Chen 2000 Efficacy of consensus interferon in the treatment of chronic hepatitis C J Gastroenterol Hepatol 15 12 1418 1423 1:CAS:528:DC%2BD3MXotFalsA%3D%3D 10.1046/j.1440-1746.2000.02371.x 11197053 (Pubitemid 32052916)
39. EB Keeffe GM Dusheiko SP James KD Mullen GT Everson NR Pimstone, et al. 1999 Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group Cytokines Cell Mol Ther 5 4 207 210 1:STN:280:DC%2BD3czgs1GmtQ%3D%3D 10850384
40. EB Keeffe GM Dusheiko MJ Tong FB Hollinger EJ Heathcote J McHutchison, et al. 1999 Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group Cytokines Cell Mol Ther 5 4 211 216 1:CAS:528:DC%2BD3cXktlWku7o%3D 10850385
41. TJ Layden JE Layden KR Reddy RS Levy-Drummer J Poulakos AU Neumann 2002 Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C J Viral Hepat 9 5 334 339 10.1046/j.1365-2893.2002.00376.x 12225327
42. L Miglioresi M Bacosi F Russo F Patrizi P Saccenti A Ursitti, et al. 2003 Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection Hepatol Res 27 4 253 259 1:CAS:528: DC%2BD3sXps1Ors7k%3D 10.1016/S1386-6346(03)00269-9 14662112 (Pubitemid 38009009)
43. PJ Pockros R Reindollar J McHutchinson R Reddy T Wright DG Boyd, et al. 2003 The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients J Viral Hepat 10 1 55 60 1:STN:280:DC%2BD3s7gtlyitA%3D%3D 10.1046/j.1365-2893.2003.00402.x 12558913 (Pubitemid 36237813)
44. PJ Pockros M Tong WM Lee DJ van Leeuwen EB Keeffe K Bala, et al. 1998 Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group J Viral Hepat 5 4 271 276 1:STN:280:DyaK1cvitlGrug%3D%3D 10.1046/j.1365-2893.1998.00114. x 9751014 (Pubitemid 28358231)
45. KR Reddy JH Hoofnagle MJ Tong WM Lee P Pockros EJ Heathcote, et al. 1999 Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group Hepatology 30 3 787 793 1:CAS:528: DyaK1MXmtVSkt7c%3D 10.1002/hep.510300319 10462387 (Pubitemid 29409425)
46. H Saito S Tada H Ebinuma H Ishii K Kashiwazaki J Nishida, et al. 2006 Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C Keio J Med 55 3 111 117 1:CAS:528:DC%2BD28Xht1GktbrF 10.2302/kjm.55.111 17008803 (Pubitemid 44544853)
47. MH Sjogren R Sjogren K Holtzmuller B Winston B Butterfield S Drake, et al. 2005 Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C Dig Dis Sci 50 4 727 732 1:CAS:528:DC%2BD2MXivVKhtbg%3D 10.1007/s10620-005-2564-2 15844709 (Pubitemid 40558468)
48. MH Sjogren R Sjogren Jr MF Lyons M Ryan J Santoro C Smith, et al. 2007 Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin Dig Dis Sci 52 6 1540 1547 1:CAS:528:DC%2BD2sXltlaqt7w%3D 10.1007/s10620-007-9757-9 17406822 (Pubitemid 46776512)
49. H Suzuki K Sato H Takagi D Kanda N Sohara S Kakizaki, et al. 2006 Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2 World J Gastroenterol 12 6 945 950 1:CAS:528:DC%2BD28XjsFertbk%3D 16521225
50. H Suzuki T Tango 2002 A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection Hepatol Res 22 1 1 12 1:CAS:528:DC%2BD38XislSmsLo%3D 10.1016/S1386-6346(01)00139-5 11804828 (Pubitemid 34223628)
51. MJ Tong KR Reddy WM Lee PJ Pockros JC Hoefs EB Keeffe, et al. 1997 Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group Hepatology 26 3 747 754 1:CAS:528:DyaK2sXmt1CktrY%3D 10.1002/hep.510260330 9303508
52. GB Yao XX Fu GS Tian DZ Xu LJ Hao YS Huangfu, et al. 2000 A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection J Gastroenterol Hepatol 15 10 1165 1170 1:CAS:528:DC%2BD3cXosl2qs70%3D 10.1046/j.1440-1746.2000.02307.x 11106097
53. R MacNicholas S Norris 2010 Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV-the role of epoetin, G-CSF and novel agents Aliment Pharmacol Ther 31 9 929 937 1:CAS:528:DC%2BC3cXmtFOgs7s%3D
54. MR Kraus A Schafer K Schottker C Keicher B Weissbrich I Hofbauer, et al. 2008 Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study Gut 57 4 531 536 1:CAS:528:DC%2BD1cXltVKntbc%3D 10.1136/gut.2007.131607 18079286 (Pubitemid 351442539)
55. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev (1):MR000006
56. EH Turner AM Matthews E Linardatos RA Tell R Rosenthal 2008 Selective publication of antidepressant trials and its influence on apparent efficacy N Engl J Med 358 3 252 260 1:CAS:528:DC%2BD1cXms12huw%3D%3D 10.1056/NEJMsa065779 18199864
57. D Moher A Jones L Lepage 2001 Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation JAMA 285 15 1992 1995 1:STN:280:DC%2BD3M3kvFaguw%3D%3D 10.1001/jama.285.15.1992 11308436